Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Crotamiton→

Crotamiton PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
483-63-6
Molecular formula
C13H17NO
Molecular weight
203.28 g/mol
Drug class
Topical antipruritic and scabicidelocal ectoparasiticide
Mechanism of action
The precise mechanism is not fully understood. Crotamiton has antipruritic effects and scabicidal activity, likely through local effects on mite physiology and sensory pathways.
Indications / reported uses
  • Topical treatment of scabies in adults and children where authorised
  • Temporary relief of itching associated with selected pruritic skin conditions; use on appropriate skin areas and according to product instructions

Sources: US DailyMed — Crotamiton cream/lotion · NLM MeSH — Crotamiton · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Topical antipruritic and scabicide; local ectoparasiticide

Mechanism of action

The precise mechanism is not fully understood. Crotamiton has antipruritic effects and scabicidal activity, likely through local effects on mite physiology and sensory pathways.

General use cases

  • Topical treatment of scabies in adults and children where authorised
  • Temporary relief of itching associated with selected pruritic skin conditions; use on appropriate skin areas and according to product instructions

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Crotamiton PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Crotamiton Permitted Daily Exposure (PDE) report (the Crotamiton PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Crotamiton Occupational Exposure Limit (OEL) report (the Crotamiton OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.